Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Radiation after lumpectomy may be unnecessary for many older women

02.09.2004


Tamoxifen alone may adequately control breast cancer, avoiding side effects



Older women treated with tamoxifen after removal of early-stage breast cancer by lumpectomy may safely be able to avoid radiation therapy and its unpleasant side effects. In the Sept. 2 New England Journal of Medicine, investigators from several major cancer research groups report that adding radiation to post-surgical tamoxifen treatment of women age 70 or older does not improve survival, has minimal impact on the risk of local tumor recurrence and does not prevent the need for eventual mastectomy. “If a patient does not need to have radiation therapy, her quality of life can improve significantly,” says Kevin Hughes, MD, of the Massachusetts General Hospital (MGH) Cancer Center, who led the study. “By showing that radiation therapy has very little impact on outcome for these patients, we can help each woman and her physician decide on the right treatment.”

Many breast cancers depend on the hormone estrogen to grow. So tamoxifen, which blocks the interaction between estrogen and its receptor protein, is used to treatment tumors that have that protein on the surface of their cells. Most older breast cancer patients have receptor-positive tumors and receive tamoxifen, a medication that has few side effects.


Radiation has been a standard post-surgical treatment for women having lumpectomies, but the therapy can be both inconvenient and unpleasant, with side effects such as pain, swelling, and skin discoloration. Several studies have shown that, although radiation reduces tumor recurrence, it does not improve overall survival. Because breast cancer is less likely to recur in older women, the research team investigated whether such patients might do well if they receive tamoxifen alone after surgery.

Over a five-year period, more than 600 patients at almost 30 centers across the U.S. enrolled in the study. All the participants were age 70 or older, with early-stage (2 cm or less), receptor-positive tumors that had been removed in lumpectomy procedures. They were randomly assigned to receive either tamoxifen alone or tamoxifen plus radiation as postsurgical treatment.

At the end of the study period, the only significant difference between the groups was in the risk that the tumor would recur at or near its original site. Both groups had very low rates of recurrence; but while those in the tamoxifen-only group had a 4 percent risk, those who also received radiation had an only 1 percent risk. There were no significant differences in terms of distant metastasis, the need for mastectomy after recurrence or overall survival. Both groups had exactly the same number of breast cancer deaths – three in each group, a rate that reflects the less aggressive nature of breast cancer in this age group. As expected, those receiving radiation reported more pain, swelling, stiffness and other side effects than did the tamoxifen-only participants.

“The local recurrence risk in both groups was extremely low, and women who have not had radiation have the option of another lumpectomy if they do have recurrence in the same breast. Once a patient has had radiation, however, she must have a mastectomy if her tumor recurs,” says Hughes, an assistant professor of Surgery at Harvard Medical School. “In the long run, each woman and her physician should choose a treatment plan by weighing the slightly increased local recurrence risk against the virtually certain costs of radiation – the patient’s time, adverse effects, and financial costs.”

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu

All articles from Materials Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>